These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27206386)

  • 21. Protection of mice by equine herpesvirus type 1 based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies.
    Rosas CT; Paessler S; Ni H; Osterrieder N
    Am J Trop Med Hyg; 2008 Jan; 78(1):83-92. PubMed ID: 18187789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designing multivalent immunogens for alphavirus vaccine optimization.
    Read CM; Plante K; Rafael G; Rossi SL; Braun W; Weaver SC; Schein CH
    Virology; 2021 Sep; 561():117-124. PubMed ID: 33823988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
    Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
    Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge.
    Rossi SL; Russell-Lodrigue KE; Killeen SZ; Wang E; Leal G; Bergren NA; Vinet-Oliphant H; Weaver SC; Roy CJ
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003797. PubMed ID: 26020513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Jan; 28(4):1031-40. PubMed ID: 19914193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
    Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
    Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination.
    Perkins SD; O'Brien LM; Phillpotts RJ
    Vaccine; 2006 Apr; 24(17):3440-5. PubMed ID: 16527377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.
    Greenway TE; Eldridge JH; Ludwig G; Staas JK; Smith JF; Gilley RM; Michalek SM
    Vaccine; 1998 Aug; 16(13):1314-23. PubMed ID: 9682396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine.
    Greenway TE; Eldridge JH; Ludwig G; Staas JK; Smith JF; Gilley RM; Michalek SM
    Vaccine; 1995; 13(15):1411-20. PubMed ID: 8578818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Erasmus JH; Seymour RL; Kaelber JT; Kim DY; Leal G; Sherman MB; Frolov I; Chiu W; Weaver SC; Nasar F
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29187545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.
    Atasheva S; Kim DY; Frolova EI; Frolov I
    J Virol; 2015 Jan; 89(1):71-82. PubMed ID: 25320296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.
    Fine DL; Roberts BA; Terpening SJ; Mott J; Vasconcelos D; House RV
    Vaccine; 2008 Jun; 26(27-28):3497-506. PubMed ID: 18508163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
    Phillpotts RJ; Lescott TL; Jacobs SC
    Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.
    Suschak JJ; Bixler SL; Badger CV; Spik KW; Kwilas SA; Rossi FD; Twenhafel N; Adams ML; Shoemaker CJ; Spiegel E; Hooper JW
    NPJ Vaccines; 2022 Apr; 7(1):46. PubMed ID: 35459271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
    Williams M; Ewing D; Blevins M; Sun P; Sundaram AK; Raviprakash KS; Porter KR; Sanders JW
    Vaccine; 2019 Jul; 37(32):4444-4453. PubMed ID: 31279565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Spearman P; Mulligan M; Anderson EJ; Shane AL; Stephens K; Gibson T; Hartwell B; Hannaman D; Watson NL; Singh K
    Vaccine; 2016 Nov; 34(46):5571-5578. PubMed ID: 27697302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.
    Rusnak JM; Dupuy LC; Niemuth NA; Glenn AM; Ward LA
    Comp Med; 2018 Oct; 68(5):380-395. PubMed ID: 30282570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.